8. Available data for comparison 6 (low dose vs high dose NSAID).
| Trial | Groups | Pain on Likert scale | Pain on VAS | Withdrawals due to adverse events | BASDAI | Patient's global assessment of disease activity | Duration of morning stiffness | CRP | ASAS20 | ASAS partial remission | BASFI | BASMI | Chest expansion | Schober's test | Pain relief ≥ 50% | Number of any adverse events | Number of serious adverse events | Adverse events per organ system |
| Barkhuizen 2006 | Celecoxib 200 mg vs Celecoxib 400 mg | * | + | * | * | * | * | + | * | + | + | + | ||||||
| Dougados 1994 | Ximoprofen 5 mg vs Ximoprofen 30 mg | + | + | + | + | + | + | + | ||||||||||
| Dougados 1999 | Meloxicam 15 mg vs Meloxicam 22.5 mg | + | + | + | + | + | + | + | + | * | * | |||||||
| Sieper 2008 | Celecoxib 200 mg vs Celecoxib 400 mg | + | + | + | + | + | + | + | + | + | + | + | ||||||
| van der Heijde 2005 | Etoricoxib 90 mg vs Etoricoxib 120 mg | + | + | + | + | + | + | + | + | + | + | + | + |
+ Available data that was used in the meta‐analysis. * Available data that could not be used in the meta‐analysis. Additional information on all included trials can be found in the Characteristics of included studies.